Day 3 Recap: SDPA Annual Summer Dermatology Conference 2025

To stay informed with the latest conference insights, subscribe to receive our eNewsletters.

Dupilumab Maintains Long-Term Flare Control Across Dosing Regimens in Atopic Dermatitis

A year-long study showed dupilumab alone effectively prevented flares in moderate to severe atopic dermatitis, with consistent safety across various dosing schedules.

Color as a Clinical Compass for Skin Cancer Detection

Orit Markowitz, MD, shares how a color-focused strategy helps spot early malignancies—even 2 mm lesions—across all skin tones.

Sustaining Repigmentation in Vitiligo Requires Gradual Step-Down Approach, Says Gina Mangin, PA-C

Ongoing maintenance therapy is essential to avoid relapse and preserve gains in repigmentation for patients with vitiligo, according to Gina Mangin, MPAS, PA-C.

Study Reports Low Incidence of Injection Site Reactions in Nemolizumab-Treated Patients

Nearly all injection site reactions among patients in the ARCADIA 1/2 and OLYMPIA 1/2 clinical trials were mild and transient in nature.

Amy Spizuoco, DO, FAOCD: Trichoscopy Improves Precision and Efficiency in Alopecia Diagnosis

Amy Spizuoco, DO, FAOCD, shared how trichoscopy enhances alopecia evaluation by improving diagnostic speed, accuracy, and reducing biopsy need.

Q&A: David Cotter, MD, PhD, Advancing Alopecia Areata Care With Systemic Therapies

David Cotter, MD, PhD, discusses diagnosing alopecia areata and selecting systemic treatments, including JAK inhibitors, from his SDPA 2025 presentation.

Roflumilast Foam 0.3% Demonstrates Favorable Pigmentation Profile in Seborrheic Dermatitis

A poster evaluating the STRATUM trial showed roflumilast foam 0.3% effectively treats seborrheic dermatitis with minimal pigment changes.

Make sure to keep up to date with the latest in coverage from the conference and subscribe to Dermatology Times to receive daily email updates.